Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Aug 29;12(2):135–148. doi: 10.1111/j.1527-3458.2006.00135.x

Involvement of Calpain Activation in Neurodegenerative Processes

Antoni Camins 1, Ester Verdaguer 2, Jaume Folch 3, Mercè Pallàs 1,✉
PMCID: PMC6494133  PMID: 16958987

ABSTRACT

One of the challenges in the coming years will be to better understand the mechanisms of neuronal cell death with the objective of developing adequate drugs for the treatment of neurodegenerative disorders. Caspases and calpains are among the best‐characterized cysteine proteases activated in brain disorders. Likewise, during the last decade, extensive research revealed that the deregulation of calpains activity is a key cytotoxic event in a variety of neurodegenerative disorders. Moreover, interest in the role of calpain in neurodegenerative processes is growing due to implication of the involvement of cdk5 in neurodegenerative diseases. Since calpain inhibitors appear to not only protect brain tissue from ischemia, but also to prevent neurotoxicity caused by such neurotoxins as β‐amyloid or 3‐nitropropionic acid, the currently available data suggest that calpain and cdk5 play a key role in neuronal cell death. It seems clear that the inappropriate activation of cysteine proteases occurs not only during neuronal cell death, but may also contribute to brain pathology in ischemia and traumatic brain disorders. Pharmacological modulation of calpain activation may, therefore, be useful in the treatment of neurodegenerative disorders. It is possible, although difficult, to develop synthetic inhibitors of cysteine proteases, specifically calpains. The inhibition of calpain activation has recently emerged as a potential therapeutic target for the treatment of neurodegenerative diseases.

Keywords: Amyloid, Calpain, Caspase, Excitotoxicity, Glutamate, Mitochondria, Neurodegenerative diseases

Full Text

The Full Text of this article is available as a PDF (183.4 KB).

REFERENCES

  • 1. Alavez S, Moran J, Franco‐Cea A, Ortega‐Gomez A, Casaletti L, Cameron LC. Myosin Va is proteolysed in rat cerebellar granule neurons after excitotoxic injury. Neurosci Lett 2004;367(9):404–409. [DOI] [PubMed] [Google Scholar]
  • 2. Alvarez A, Toro R, Caceres A, Maccioni RB. Inhibition of tau phosphorylating protein kinase cdk5 prevents beta‐amyloid‐induced neuronal death. FEBS Lett 1999;459: 421–426. [DOI] [PubMed] [Google Scholar]
  • 3. Araujo IM, Verdasca MJ, Leal EC, et al. Early calpain‐mediated proteolysis following AMPA receptor activation compromises neuronal survival in cultured hippocampal neurons. J Neurochem 2004;91: 1322–1331. [DOI] [PubMed] [Google Scholar]
  • 4. Banay‐Schwartz M, DeGuzman T, Palkovits M, Lajtha A. Calpain activity in adult and aged human brain regions. Neurochem Res 1994;19: 563–567. [DOI] [PubMed] [Google Scholar]
  • 5. Bano D, Young KW, Guerin CJ, et al. C leavage of the plasma membrana Na+/Ca2+ exchanger in excitotoxicity. Cell 2005;120: 275–285. [DOI] [PubMed] [Google Scholar]
  • 6. Bartus RT, Hayward NJ, Elliott PJ, et al. Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of postocclusion intra‐arterial administration. Stroke 1994;25: 2265–2270. [DOI] [PubMed] [Google Scholar]
  • 7. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O. Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J Mol Neurosci 2003;20: 357–362. [DOI] [PubMed] [Google Scholar]
  • 8. Benuck M, Banay‐Schwartz M, DeGuzman T, Lajtha A. Changes in brain protease activity in aging. J Neurochem 1996;67: 2019–2029. [DOI] [PubMed] [Google Scholar]
  • 9. Biswas S, Harris F, Dennison S, Singh J, Phoenix DA. Calpains: Targets of cataract prevention Trends Mol Med 2004;10: 78–84. [DOI] [PubMed] [Google Scholar]
  • 10. Bizat N, Galas MC, Jacquard C, et al. Neuroprotective effect of zVAD against the neurotoxin 3‐nitropropionic acid involves inhibition of calpain. Neuropharmacology 2005;49: 695–702. [DOI] [PubMed] [Google Scholar]
  • 11. Bizat N, Hermel JM, Boyer F, et al. C alpain is a major cell death effector in selective striatal degeneration induced in vivo by 3‐nitropropionate: Implications for Huntington's disease. J Neurosci 2003;23: 5020–5030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Bernath E, Kupina N, Liu MC, Hayes RL, Meegan C, Wang KK. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging 2006;27: 624–632. [DOI] [PubMed] [Google Scholar]
  • 13. Brion JP, Couck AM. Cortical and brainstem‐type Lewy bodies are immunoreactive for the cyclin‐dependent kinase 5. Am J Pathol 1995;147: 1465–1476. [PMC free article] [PubMed] [Google Scholar]
  • 14. Buki A, Farkas O, Doczi T, Povlishock JT. Preinjury administration of the calpain inhibitor MDL‐28170 attenuates traumatically induced axonal injury. J Neurotrauma 2003;20: 261–268. [DOI] [PubMed] [Google Scholar]
  • 15. Carragher NO. Calpain inhibition: A therapeutic strategy targeting multiple disease states. Curr Pharm Des 2006;12: 615–638. [DOI] [PubMed] [Google Scholar]
  • 16. Chen M, He H, Zhan S, Krajewski S, Reed JC, Gottlieb RA. B id is cleaved by calpain to an active fragment in vitro and during myocardial ischemia/([a‐z])eperfusion. J Biol Chem 2001;276: 30724–30728. [DOI] [PubMed] [Google Scholar]
  • 17. Chen MJ, Yap YW, Choy MS, et al. Early induction of calpains in rotenone‐mediated neuronal apoptosis. Neurosci Lett 2006;397: 69–73. [DOI] [PubMed] [Google Scholar]
  • 18. Choi WS, Lee EH, Chung CW, et al. Cleavage of Bax is mediated by caspase‐dependent or ‐independent calpain activation in dopaminergic neuronal cells: Protective role of Bcl‐2. J Neurochem 2001;77: 1531–1541. [DOI] [PubMed] [Google Scholar]
  • 19. Crocker SJ, Smith PD, Jackson‐Lewis V, et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J Neurosci 2003;23: 4081–4091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends Mol Med 2004;10: 452–458. [DOI] [PubMed] [Google Scholar]
  • 21. Das A, Sribnick EA, Wingrave JM, et al. Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: Calpain inhibition provides functional neuroprotection. J Neurosci Res 2005;81: 551–562. [DOI] [PubMed] [Google Scholar]
  • 22. Donkor IO, Sanders ML. S Streptomyces griseus. Bioorg Med Chem Lett 2001;11: 2647–2649. [DOI] [PubMed] [Google Scholar]
  • 23. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Nakamura M, Shearer TR. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: Amelioration of cataract in cultured rat lenses. Biochim Biophys Acta 1997;1361: 304–312. [DOI] [PubMed] [Google Scholar]
  • 24. Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci 2002;22: 4842–4849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Giese KP, Ris L, Plattner F. Is there a role of the cyclin‐dependent kinase 5 activator p25 in Alzheimer's disease Neuroreport 2005;16: 1725–1730. [DOI] [PubMed] [Google Scholar]
  • 26. Gonzalez‐Polo RA, Soler G, Fuentes JM. M PP+: Mechanism for its toxicity in cerebellar granule cells. Mol Neurobiol 2004;30: 253–64. [DOI] [PubMed] [Google Scholar]
  • 27. Gray BC, Skipp P, O'connor VM, Perry VH. Increased expression of glial fibrillary acidic protein fragments and μ‐calpain activation within the hippocampus of prion‐infected mice. Biochem Soc Trans 2006;34: 51–54. [DOI] [PubMed] [Google Scholar]
  • 28. Hung KS, Hwang SL, Liang CL, et al. Calpain inhibitor inhibits p35‐p25‐Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J Neuropathol Exp Neurol 2005;64: 15–26. [DOI] [PubMed] [Google Scholar]
  • 29. Kesavapany S, Li BS, Amin N, Zheng YL, Grant P, Pant HC. Neuronal cyclin‐dependent kinase 5: Role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide. Biochim Biophys Acta 2004;1697: 143–153. [DOI] [PubMed] [Google Scholar]
  • 30. Kieran D, Greensmith L. Inhibition of calpains, by treatment with leupeptin, improves motoneuron survival and muscle function in models of motoneuron degeneration. Neuroscience 2004;125: 427–39. [DOI] [PubMed] [Google Scholar]
  • 31. Kupina NC, Detloff MR, Bobrowski WF, Snyder BJ, Hall ED. Cytoskeletal protein degradation and neuro‐degeneration evolves differently in males and females following experimental head injury. Exp Neurol 2003;180: 55–73. [DOI] [PubMed] [Google Scholar]
  • 32. Lee KS, Seo SH, Lee YH, et al. Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors. Bioorg Med Chem Lett 2005;15: 2857–2860. [DOI] [PubMed] [Google Scholar]
  • 33. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;18: 405: 360–364. [DOI] [PubMed] [Google Scholar]
  • 34. Leist M, Volbracht C, Fava E, Nicotera P. 1‐Methyl‐4‐phenylpyridinium induces autocrine excitotoxicity, protease activation, and neuronal apoptosis. Mol Pharmacol 1998;54: 789–801. [DOI] [PubMed] [Google Scholar]
  • 35. Li J, Nixon R, Messer A, Berman S, Bursztajn S. Altered gene expression for calpain/([a‐z])alpastatin system in motor neuron degeneration (Mnd) mutant mouse brain and spinal cord. Brain Res Mol Brain Res 1998;53: 174–186. [DOI] [PubMed] [Google Scholar]
  • 36. Liou AK, Zhou Z, Pei W, Lim TM, Yin XM, Chen J. BimEL up‐regulation potentiates AIF translocation and cell death in response to MPTP. FASEB J 2005;19: 1350–1352. [DOI] [PubMed] [Google Scholar]
  • 37. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79: 1431–568. [DOI] [PubMed] [Google Scholar]
  • 38. Liu F, Grundke‐Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 2005;280: 37755–37762. [DOI] [PubMed] [Google Scholar]
  • 39. Liu T, Perry G, Chan HW, Verdile G, et al. Amyloid‐beta‐induced toxicity of primary neurons is dependent upon differentiation‐associated increases in tau and cyclin‐dependent kinase 5 expression. J Neurochem 2004;88: 554–563. [DOI] [PubMed] [Google Scholar]
  • 40. Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. Arch Med Res 2001;32: 367–381. [DOI] [PubMed] [Google Scholar]
  • 41. McCollum AT, Nasr P, Estus S. Calpain activates caspase‐3 during UV‐induced neuronal death but only calpain is necessary for death. J Neurochem 2002;82: 1208–1220. [DOI] [PubMed] [Google Scholar]
  • 42. Momeni HR, Kanje M. The calpain inhibitor VI prevents apoptosis of adult motor neurons. Neuroreport 2005;16: 1065–1068. [DOI] [PubMed] [Google Scholar]
  • 43. Moore JD, Rothwell NJ, Gibson RM. Involvement of caspases and calpains in cerebrocortical neuronal cell death is stimulus‐dependent. Br J Pharmacol 2002;135: 1069–1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Mouatt‐Prigent A, Karlsson JO, Agid Y, Hirsch EC. Increased m‐calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: A role in nerve cell death Neuroscience 1996;73: 979–987. [DOI] [PubMed] [Google Scholar]
  • 45. Nakamura M, Yamaguchi M, Sakai O, Inoue J. Exploration of cornea permeable calpain inhibitors as anti‐cataract agents. Bioorg Med Chem 2003;11: 1371–1379. [DOI] [PubMed] [Google Scholar]
  • 46. Nakamura S, Kawamoto Y, Nakano S, Akiguchi I, Kimura J. p35nck5a and cyclin‐dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease. Acta Neuropathol (Berl) 1997;94: 153–157. [DOI] [PubMed] [Google Scholar]
  • 47. Nasr P, Gursahani HI, Pang Z, et al. I nfluence of cytosolic and mitochondrial Ca2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism of neuron death induced by 3‐nitropropionic acid. Neurochem Int 2003;43: 89–99. [DOI] [PubMed] [Google Scholar]
  • 48. Neumar RW, Xu YA, Gada H, Guttmann RP, Siman R. Cross‐talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem 2003;278: 14162–14167. [DOI] [PubMed] [Google Scholar]
  • 49. Nixon RA. The calpains in aging and aging‐related diseases. Ageing Res Rev 2003;2: 407–418. [DOI] [PubMed] [Google Scholar]
  • 50. Nixon RA, Saito KI, Grynspan F, et al. Calcium‐activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann NY Acad Sci 1994;747: 77–91. [DOI] [PubMed] [Google Scholar]
  • 51. O'Donovan CN, Tobin D, Cotter TG. Prion protein fragment PrP‐(106–126) induces apoptosis via mitochondrial disruption in human neuronal SH‐SY5Y cells. J Biol Chem 2001;276: 43516–43523. [DOI] [PubMed] [Google Scholar]
  • 52. Oh SH, Lee BH, Lim SC. Cadmium induces apoptotic cell death in WI 38 cells via caspase‐dependent Bid cleavage and calpain‐mediated mitochondrial Bax cleavage by Bcl‐2‐independent pathway. Biochem Pharmacol 2004;68: 1845–1855. [DOI] [PubMed] [Google Scholar]
  • 53. O'Hare MJ, Kushwaha N, Zhang Y, et al. Differential roles of nuclear and cytoplasmic cyclin‐dependent kinase 5 in apoptotic and excitotoxic neuronal death. J Neurosci 2005;25: 8954–89566. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Pang Z, Bondada V, Sengoku T, Siman R, Geddes JW. Calpain facilitates the neuron death induced by 3‐nitropropionic acid and contributes to the necrotic morphology. J Neuropathol Exp Neurol 2003;62: 633–643. [DOI] [PubMed] [Google Scholar]
  • 55. Pike BR, Flint J, Dutta S, Johnson E, Wang KK, Hayes RL. Accumulation of non‐erythroid alpha II‐spectrin and calpain‐cleaved alpha II‐spectrin breakdown products in cerebrospinal fluid after traumatic brain injury in rats. J Neurochem 2001;78: 1297–1306. [DOI] [PubMed] [Google Scholar]
  • 56. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis‐inducing factor from isolated mitochondria. J Biol Chem 2005;280: 6447–6454. [DOI] [PubMed] [Google Scholar]
  • 57. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol 2004;14: 215–222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Rami A, Agarwal R, Botez G, Winckler J. μ‐Calpain activation, DNA fragmentation, and synergistic effects of caspase and calpain inhibitors in protecting hippocampal neurons from ischemic damage. Brain Res 2000;866: 299–312. [DOI] [PubMed] [Google Scholar]
  • 59. Saatman KE, Murai H, Bartus RT, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci USA 1996;93: 3428–3433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium‐activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 1993;90: 2628–2632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Saulle E, Gubellini P, Picconi B, et al. Neuronal vulnerability following inhibition of mitochondrial complex II: Apossible ionic mechanism for Huntington's disease. Mol Cell Neurosci 2004;25: 9–20. [DOI] [PubMed] [Google Scholar]
  • 62. Sedarous M, Keramaris E, O'Hare M, et al. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 2003;278: 26031–26038. [DOI] [PubMed] [Google Scholar]
  • 63. Sen A, Thom M, Martinian L, Jacobs T, Nikolic M, Sisodiya SM. Deregulation of cdk5 in hippocampal sclerosis. J Neuropathol Exp Neurol 2006;65: 55–66. [DOI] [PubMed] [Google Scholar]
  • 64. Sharma AK, Rohrer B. Calcium‐induced calpain mediates apoptosis via caspase‐3 in a mouse photoreceptor cell line. J Biol Chem 2004;279: 35564–35572. [DOI] [PubMed] [Google Scholar]
  • 65. Selvakumar P, Smith‐Windsor E, Bonham K, Sharma RK. N‐Myristoyltransferase 2 expression in human colon cancer: Cross‐talk between the calpain and caspase system. FEBS Lett 2006;580: 2021–2026. [DOI] [PubMed] [Google Scholar]
  • 66. Siman R, Gall C, Perlmutter LS, Christian C, Baudry M, Lynch G. Distribution of calpain I, an enzyme associated with degenerative activity, in rat brain. Brain Res 1985;347: 399–403. [DOI] [PubMed] [Google Scholar]
  • 67. Smith PD, Crocker SJ, Jackson‐Lewis V, et al. Cyclin‐dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2003;100: 13650–13655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Smith PD, Mount MP, Shree R, et al. Calpain‐regulated p35/([a‐z])dk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 2006;26: 440–447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid‐beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 2002;33: 1194–1199. [DOI] [PubMed] [Google Scholar]
  • 70. Strachan GD, Koike MA, Siman R, Hall DJ, Jordan‐Sciutto KL. E2F1 induces cell death, calpain activation, and MDMX degradation in a transcription independent manner implicating a novel role for E2F1 in neuronal loss in SIV encephalitis. J Cell Biochem 2005;96: 728–740. [DOI] [PubMed] [Google Scholar]
  • 71. Takano J, Tomioka M, Tsubuki S, et al. Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem 2005;280: 16175–16184. [DOI] [PubMed] [Google Scholar]
  • 72. Tsai LH, Lee MS, Cruz J. Cdk5, a therapeutic target for Alzheimer's disease Biochim Biophys Acta 2004;1697: 137–142. [DOI] [PubMed] [Google Scholar]
  • 73. Van den Bosch L, Van Damme P, Vleminckx V, et al. A n alpha‐mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate‐induced Ca2+ influx and not via calpain inhibition. Neuropharmacology 2002;42: 706–713. [DOI] [PubMed] [Google Scholar]
  • 74. Veeranna Kaji T, Boland B, Odrljin T, et al. Calpain mediates calcium‐induced activation of the erk1, 2 MAPK pathway and cytoskeletal phosphorylation in neurons: Relevance to Alzheimer's disease. Am J Pathol 2004;165: 795–805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Wang KK, Nath R, Posner A, et al. An alpha‐mercaptoacrylic acid derivative is a selective nonpeptide cell‐permeable calpain inhibitor and is neuroprotective. Proc Natl Acad Sci USA 1996;93: 6687–6692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD. Calpain inhibition protects against taxol‐induced sensory neuropathy. Brain 2004;127: 671–679. [DOI] [PubMed] [Google Scholar]
  • 77. Warren MW, Kobeissy FH, Liu MC, Hayes RL, Gold MS, Wang KK. Concurrent calpain and caspase‐3 mediated proteolysis of alpha II‐spectrin and tau in rat brain after methamphetamine exposure: A similar profile to traumatic brain injury. Life Sci 2005;78: 301–309. [DOI] [PubMed] [Google Scholar]
  • 78. Wood DE, Newcomb EW. Caspase‐dependent activation of calpain during drug‐induced apoptosis. Biol Chem 1999;274: 8309–8315. [DOI] [PubMed] [Google Scholar]
  • 79. Wood DE, Thomas A, Devi LA, et al. Bax cleavage is mediated by calpain during drug‐induced apoptosis. Oncogene 1998;17: 1069–1078. [DOI] [PubMed] [Google Scholar]
  • 80. Yadavalli R, Guttmann RP, Seward T, Centers AP, Williamson RA, Telling GC. Calpain‐dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation. J Biol Chem 2004;279: 21948–21956. [DOI] [PubMed] [Google Scholar]
  • 81. Yamashima T. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog Neurobiol 2000;62: 273–295. [DOI] [PubMed] [Google Scholar]
  • 82. Yang L, Sugama S, Mischak RP, et al. A in vivo. Neurobiol Dis 2004;17: 250–259. [DOI] [PubMed] [Google Scholar]
  • 83. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005;352: 2413–2423. [DOI] [PubMed] [Google Scholar]
  • 84. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I. Cyclin‐dependent kinase inhibitors attenuate protein hyper‐phosphorylation, cytoskeletal lesion formation, and motor defects in Niemann‐Pick Type C mice. Am J Pathol 2004;165: 843–853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Zheng YL, Kesavapany S, Gravell M, et al. A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 2005;24: 209–220. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES